SweDeliver receives continued funding 2025-2029
SweDeliver, National Competence Center in Drug Delivery, will receive continued funding for another five years. The decision is announced by Swedish innovation agency Vinnova, that in a new evaluation award very high grades to SweDeliver's first four years of operation. Vinnova's funding can amount to SEK 36 million, with additional funding the center's total value is expected to reach SEK 108 million.
“This is fantastic news for SweDeliver's partners and junior researchers whose inspiring commitment is decisive for our progress. It is also very good news for pharmaceutical researchers and care recipients worldwide who already are or will greatly benefit from SweDeliver's scientific results,” says Christel Bergström, Center Director and Professor of Molecular Pharmacutics.
SweDeliver launched in 2020 as a continuation of the Swedish Drug Delivery Forum. With academic hub in Uppsala, the University's Faculty of Pharmacy, in collaboration with 18 industrial partners, leads research with a focus on challenges in Parenteral, Oral and Pulmonary drug delivery. Numerous previous evaluations have already accentuated SweDeliver's strong scientific position, not least the work in Oral drug delivery, repeatedly ranked among the world's foremost with results that have great international impact.
Bertil Abrahamsson, Chair, SweDeliver
“To me, Vinnova's announcement is an acknowledgment of the extraordinary work provided by everyone engaged in SweDeliver. Today, we have established a unique structure that arouses commitment far beyond Sweden's borders, a fact confirmed by industry giants Janssen Pharmaceuticals and Chiesi joining our network. The fact that we are now building for another five years gives us room to ensure long-term progress in our field,” states Bertil Abrahamsson, chair of SweDeliver and Senior principal scientist at AstraZeneca.
The important work of outlining SweDeliver 2.0 is already underway and applications for future research are to be submitted this autumn. Before that, several of SweDeliver's industry partners will welcome the highly promising master's students selected for a six-week summer internship in ongoing research projects. The agenda also includes SweDeliver Summit 2024, an arena where the center's junior researchers and partners will meet to discuss current research and potential projects.
“SweDeliver is an environment characterised by openness and generosity, and for us as a small player with great potential, the knowledge exchanges offered within SweDeliver are absolutely invaluable. So the announcement of five new years with SweDeliver is of course extremely significant,” says Anna Franzén, Clinical & Regulatory BDO at Emplicure, a Swedish pharmaceutical company with a focus on research and development of patentable pharmaceutical products.
In fact
- SweDeliver is a world-leading research center with a focus on new strategies for more efficient drug delivery with financial support from Vinnova.
SweDeliver focuses on important research challenges in Parenteral, Oral and Pulmonary drug delivery.
Contact
Christel Bergström, Center Director
Professor, Uppsala University
Christel.Bergstrom@farmaci.uu.se
Bertil Abrahamsson, Chair
Senior principal scientist, AstraZeneca
Bertil.Abrahamsson@astrazeneca.com
Text: Magnus Alsne, photo: Mikael Wallerstedt a o